An extensive variety of medicines and vaccines are now disseminated to patients in low- and middle-income countries (LMICs), including new medications, generic and traditional medicines, but also substandard, spurious, falsely labelled, falsified, and counterfeit drugs. This requires the development and adaptation of post-marketing drugs safety programmes, which are not put in place in most of these developing countries. The European programme in Pharmacovigilance and Pharmacoepidemiology, Eu2P, aims to improve the knowledge and awareness of medicines-related risk and benefit by implementing a training and education platform in Pharmacovigilance and Pharmacoepidemiology for academia, industry and regulatory bodies. This challenge has been conducted in 2009 by seven Universities, the European and French Medicines Agencies and fifteen Pharmaceutical Companies who have put their strengths together in order to build the Eu2P curriculum. The Eu2P programme awards joint academic courses diplomas in Pharmacovigilance and Pharmacoepidemiology through full online training, enabling a flexible learning, anytime, any pace, at any place. As part of the Eu2P project aims, the consortium members have highlighted a specific education and training need in Pharmacovigilance and Pharmacoepidemiology for medicines-related stakeholders in developing countries. Although the Eu2P programme actually significantly supports training and education as well Master research projects of stakeholders based on LMICs, Eu2P programme cannot afford to positively answer to all requests. For the near future, the Eu2P consortium is looking for new partnerships and financial solutions in order to increase support towards students and professionals who live in developing countries and wish to further study how to ensure drug patient safety first.